Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Wolverine Stack 50s Age Specific Protocol: Peptide Selection Comparison

MK 677 (Ibutamoren) Ghrelin receptor agonist. Stimulates endogenous GH release without HPTA suppression 12.5–25mg/day (higher than standard 10–20mg due to receptor desensitization) Oral capsule Must verify 3rd-party purity ≥98% Gold standard GH secretagogue fo

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • MK 677 (Ibutamoren)
  • Ghrelin receptor agonist. Stimulates endogenous GH release without HPTA suppression
  • 12.5–25mg/day (higher than standard 10–20mg due to receptor desensitization)
  • Oral capsule
  • Must verify 3rd-party purity ≥98%
  • Gold standard GH secretagogue for 50+. Oral bioavailability and preserved feedback loops make it superior to injectable alternatives for this age group
  • Thymalin
  • Thymic peptide bioregulator. Upregulates naive T-cell production and thymic epithelial function
  • 10mg/day for 10 days per cycle (vs 5–7 days in younger protocols)
  • Subcutaneous injection
  • Requires bioregulator-grade sourcing with verified peptide sequencing
  • Essential immune component. Older thymic tissue requires longer stimulation windows to respond
  • Cerebrolysin
  • Neuropeptide mixture. Supports BDNF signaling and synaptic plasticity
  • 5ml 3×/week (vs 10ml 5×/week in acute stroke protocols)
  • Intramuscular injection
  • Pharmaceutical-grade vials only. No compounded versions
  • Most evidence-backed neuroprotective option, but IM administration is a barrier for some users
  • Dihexa
  • Hexapeptide. Potent HGF/c-Met pathway activator for synaptogenesis
  • 5mg 2×/week subcutaneous (lower frequency than cognitive repair protocols)
  • Research-grade synthesis with HPLC verification
  • Emerging alternative to Cerebrolysin. Fewer injections required, but less long-term clinical data
  • CJC-1295/Ipamorelin
  • GHRH analogue + ghrelin mimetic. Synergistic GH pulse amplification
  • 200mcg/100mcg 3–4×/week (optional add-on weeks 13–16)
  • Must be non-DAC CJC-1295 to avoid desensitization
  • Effective GH pulse amplifier, but not necessary if MK 677 alone produces adequate IGF-1 response